De Novo Ventures
Boston · 5 people tracked
Find your way into De Novo Ventures
354 people in our graph share verified history with the De Novo Ventures team — schools, employers, funds. One of them is your warm intro.
Team · 5 people
from public directories
What they invest in
from 1 of 2 portfolio companiesBiotech ×1Healthtech ×1Medical Devices ×1
HQs:United States×2
Investments · 2 tracked
founders shown can be your intro path
EndoGastric Solutions offers the Transoral Incisionless Fundoplication (TIF 2.0) procedure and the EsophyX device used to treat GERD, along with reimbursement and technical/administrative support (TAP program) for medical practices.
BiotechHealthtechMedical DevicesSan Mateo, US
Philip Macdonald(Executive Officer)Louis Baldino(Executive Officer, Director)Lilip Lau(Executive Officer)Josh DeFonzo(Executive Officer)in
BoardMichael Carusi(Director)inArda Minocherhomjee(Director)
Co-investorsAccelmed PartnersCanaan PartnersEvidity Health CapitalLightstone VenturesVCFA GroupFOUNDATION MEDICAL PARTNERS+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Fund performance · per public LP disclosures · 4
as of Jun 2020| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| De Novo Ventures IIILPs: The Regents of the University of California | 2006 | — | -9.8% | 0.69x | 0.69x |
| De Novo Ventures III, L.PLPs: The Regents of the University of California | 2006 | — | -9.8% | 0.69x | 0.69x |
| De Novo Ventures IILPs: The Regents of the University of California | 2003 | — | -13.3% | 0.40x | 0.40x |
| De Novo Ventures II, L.PLPs: The Regents of the University of California | 2003 | — | -13.3% | 0.40x | 0.40x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- Where is De Novo Ventures located?
- De Novo Ventures is headquartered in Boston, US.
Co-investors · 6
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
Firms observed investing alongside De Novo Ventures, from public investor directories. Shared companies are the overlap with De Novo Ventures's recorded portfolio.